Sugi Predict

Sugi Predict / Compounds / SCHEMBL1927286

SCHEMBL1927286

SCHEMBL1927286

Cc1cn(-c2ccc(N)cc2C(F)(F)F)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR2E1 Q9Y466 1/20 0.52
▸ GLA P06280 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ PSEN1 P49768 16/20 0.41
▸ PSEN2 P49810 16/20 0.41
▸ APH1B Q8WW43 16/20 0.41
▸ NCSTN Q92542 16/20 0.41
▸ APH1A Q96BI3 16/20 0.41
▸ PSENEN Q9NZ42 16/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PDE3B Q13370 1/20 0.40
▸ KCNH2 Q12809 2/20 0.40
▸ CYP2C8 P10632 2/20 0.38
▸ CYP2C9 P11712 3/20 0.38
▸ CYP2D6 P10635 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16255769 0.85 NR2E1 (0.44) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL22704434 0.82 NR2E1 (0.43) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL12139688 0.81 NR2E1 (0.45) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL1616928 0.80 NR2E1 (0.46) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL12141129 0.80 PSEN1 (0.43) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL1616168 0.80 ALDH1A1 (0.49) NR2E1GAAPSEN1PSEN2APH1B
SCHEMBL3526697 0.79 PSEN1 (0.40) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL16923575 0.79 PSEN1 (0.46) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL3530849 0.78 NR2E1 (0.45) NR2E1PSEN1PSEN2APH1BNCSTN
SCHEMBL29958875 0.78 PSEN1 (0.52) NR2E1PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177382-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2025-06-05 — — US disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 — — EP disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
WO-2022216680-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-13 — — WO disclosed
EP-3186247-B1 PROTEIN KINASE INHIBITORS ASTAR BIOTECH LLC (US) 2021-03-03 — — EP disclosed
EP-3186247-B1 PROTEIN KINASE INHIBITORS ASTAR BIOTECH LLC (US) 2021-03-03 — — EP disclosed
EP-2880038-B1 PROTEIN KINASE INHIBITORS ASTAR BIOTECH LLC (US) 2018-05-16 — — EP disclosed
EP-2100891-A1 Inhibitors of tyrosine kinases Novartis AG (CH) 2009-09-16 — — EP disclosed
US-7569566-B2 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) NOVARTIS AG (CH) 2009-08-04 — — US disclosed
EP-1532138-B1 INHIBITORS OF TYROSINE KINASES NOVARTIS AG (CH) 2008-11-19 — — EP disclosed
US-20080188451-A1 INHIBITORS OF TYROSINE KINASES BREITENSTEIN WERNER 2008-08-07 — — US disclosed
US-20080039440-A1 Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors BOLD GUIDO 2008-02-14 — — US disclosed
US-20070093506-A1 Inhibitors of tyrosine kinases BREITENSTEIN WERNER 2007-04-26 — — US disclosed
US-7169791-B2 Inhibitors of tyrosine kinases NOVARTIS AG (CH) 2007-01-30 — — US disclosed
US-20060167015-A1 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) NOVARTIS AG (CH) 2006-07-27 — — US disclosed
EP-1532138-A1 INHIBITORS OF TYROSINE KINASES Novartis AG (CH) 2005-05-25 — — EP disclosed
WO-2004005281-A1 INHIBITORS OF TYROSINE KINASES NOVARTIS AG (CH) 2004-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093506-A1 Inhibitors of tyrosine kinases ABL1, BTK, FLT3 NR2E1 3289/4885GLA 4049/4885POLB 2751/4885
US-20080039440-A1 Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors RET, ROS1, BRAF NR2E1 252/4885GLA 4274/4885POLB 2688/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 NR2E1 589/4885GLA 3810/4885POLB 3340/4885
US-20250177382-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 NR2E1 118/4885GLA 2902/4885POLB 4015/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 NR2E1 188/4885GLA 2715/4885POLB 4139/4885
US-20080188451-A1 INHIBITORS OF TYROSINE KINASES ABL1, BTK, FLT3 NR2E1 3289/4885GLA 4049/4885POLB 2751/4885
US-20060167015-A1 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) ABL1, CDK2, CDKN1A NR2E1 1579/4885GLA 3541/4885POLB 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.